Unity Biotechnology(US:UBX)2025-03-07 21:30Financial Performance - The net loss for the year ended December 31, 2024, was $26.0 million, a decrease from $39.9 million for the year ended December 31, 2023[5]. - The total net loss for the fourth quarter of 2024 was $8.4 million, compared to $4.3 million for the fourth quarter of 2023[5]. - The net loss per share for the year ended December 31, 2024, was $1.54, compared to $2.70 for the year ended December 31, 2023[12]. Cash and Cash Equivalents - As of December 31, 2024, cash, cash equivalents, and marketable securities totaled $23.2 million, down from $43.2 million as of December 31, 2023[4]. - The company anticipates that its current cash position is sufficient to fund operations into the fourth quarter of 2025[4]. Expenses - Research and development expenses decreased by $7.1 million to $13.0 million for the year ended December 31, 2024, compared to $20.1 million for the previous year[6]. - General and administrative expenses decreased by $3.5 million to $15.5 million for the year ended December 31, 2024, from $19.0 million for the year ended December 31, 2023[8]. - The total operating expenses for the fourth quarter of 2024 were $9.99 million, compared to $7.68 million for the fourth quarter of 2023[12]. Research and Development - The company expects to receive 24-week topline data from the Phase 2b ASPIRE study in diabetic macular edema (DME) in the first quarter of 2025[2]. - The Phase 2b ASPIRE study is designed to evaluate the safety and efficacy of UBX1325 in a head-to-head comparison to aflibercept[3].